CVS Health announces split of pharmacy operations from insurance and benefits units

CVS Health, the United States’ largest healthcare conglomerate valued at $117 billion, announced on Wednesday that it will separate its pharmacy business from its health‑insurance and benefits operations. The plan creates a distinct company called CVS Pharmacy that will encompass roughly 9,000 retail locations, in‑store health clinics and the mail‑order prescription service. The remaining entity will retain the CVS Health name and continue to own the major insurer Aetna, the pharmacy‑benefits manager Caremark, and other services such as home‑visit and primary‑care offerings for older adults.

The split follows growing scrutiny from lawmakers and regulators who argue that large integrated health firms, including CVS Health, UnitedHealth Group and Cigna, wield excessive market power. Those three companies together control about 80 % of the U.S. health‑care market, and CVS Health reported revenue of more than $400 billion in the most recent fiscal year. State‑level actions in Arkansas and Tennessee have already introduced legislation aimed at preventing companies from simultaneously managing prescription benefits and operating retail or mail‑order pharmacies.

Background

The move marks a reversal of the consolidation trend that saw health‑care providers merge pharmacy, insurance and benefits functions over the past decade. CVS Health’s acquisition of Aetna in 2018 and the integration of Caremark created a vertically integrated model that combined drug dispensing, pharmacy‑benefits management and health‑insurance underwriting. Critics have contended that such integration can lead to higher costs for consumers and reduced competition. Arkansas state representative Jeremiah Moore, who sponsored a bill targeting these practices, described the situation as “crony capitalism” that exploits patients. Similar legislative proposals are under consideration in other states.

At the federal level, a bill introduced by Missouri Republican Senator Josh Hawley (the text cuts off in the source) seeks to curb the ability of large health‑care conglomerates to control both insurance and pharmacy distribution, reflecting a broader political pushback against what is termed “health‑care gigantism.”

Why it matters

The restructuring will affect a wide range of stakeholders. For consumers, the separation could lead to clearer pricing and potentially more competition in the pharmacy space, addressing concerns that integrated models inflate drug costs. Insurers and pharmacy‑benefits managers may also see shifts in negotiating power as the entities become distinct. Employees of CVS Health, estimated at over 300,000 worldwide, could face changes in corporate culture and reporting lines, though the announcement did not specify workforce impacts.

Regulators and policymakers view the split as a test case for addressing market concentration. If successful, it may encourage further antitrust actions or legislative measures aimed at other large health‑care firms. Conversely, industry analysts warn that the separation could create operational complexities and dilute economies of scale that have historically supported low‑cost drug distribution.

What happens next

CVS Health has not provided a detailed timeline for the spin‑off, but the announcement indicates that the new CVS Pharmacy will operate as a separate legal entity. The company is expected to file the necessary paperwork with the Securities and Exchange Commission and seek shareholder approval in the coming months. State and federal legislative efforts to limit integrated health‑care models are ongoing, with bills in Arkansas, Tennessee and at the federal level poised for further debate. The outcome of those measures, alongside the execution of the split, will shape the future landscape of U.S. health‑care delivery.